Piramal Pharma Limited (NSE:PPLPHARMA)

Market Cap	202.43B
Revenue (ttm)	89.36B +2.7%
Net Income	-237.40M
EPS	-0.18
Shares Out	1.33B
PE Ratio	n/a
Forward PE	96.01
Dividend	0.14 (0.09%)
Ex-Dividend Date	Jul 16, 2025

Volume	3,115,054
Average Volume	2,870,651
Open	154.00
Previous Close	152.45
Day's Range	151.55 - 154.95
52-Week Range	150.10 - 251.95
Beta	0.11
RSI	24.73
Earnings Date	Jan 28, 2026

About Piramal Pharma

Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; offers inhalation anesthetics, intrathecal therapy, inje...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2020
• Employees: 5,476
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: PPLPHARMA

Financial Performance

In 2024, Piramal Pharma's revenue was 91.51 billion, an increase of 11.99% compared to the previous year's 81.71 billion. Earnings were 911.30 million, an increase of 411.39%.